# | Date | Analyst Firm | Upside/Downside | Price Target Change | Rating Change | Current Rating |
---|
HC Wainwright & Co. analyst Andrew Fein maintains Prothena Corp (NASDAQ:PRTA) with a Buy and lowers the price target fro...
Prothena Corp (NASDAQ:PRTA) reported quarterly losses of $(1.34) per share which missed the analyst consensus estimate of $(1.2...
Prothena Corporation plc (NASDAQ:PRTA), a late-stage clinical biotechnology company with a robust pipeline of investigational t...
Cantor Fitzgerald analyst Charles Duncan reiterates Prothena Corp (NASDAQ:PRTA) with a Overweight.
HC Wainwright & Co. analyst Andrew Fein maintains Prothena Corp (NASDAQ:PRTA) with a Buy and maintains $90 price target.
JMP Securities analyst Jason Butler maintains Prothena Corp (NASDAQ:PRTA) with a Market Outperform and raises the price targ...